{"id":"NCT00151775","sponsor":"Daiichi Sankyo","briefTitle":"Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure","officialTitle":"Dose-ranging Study to Evaluate the Safety and Efficacy of Olmesartan Medoxomil in Children and Adolescents With Hypertension","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2005-05","primaryCompletion":"2008-09","completion":"2008-09","firstPosted":"2005-09-09","resultsPosted":"2010-04-02","lastUpdate":"2016-06-30"},"enrollment":362,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"olmesartan medoxomil","otherNames":["Benicar (olmesartan medoxomil)"]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"olmesartan medoxomil","otherNames":["Benicar (olmesartan medoxomil)"]}],"arms":[{"label":"Period 2","type":"EXPERIMENTAL"},{"label":"Period 3","type":"EXPERIMENTAL"},{"label":"Period 4","type":"EXPERIMENTAL"}],"summary":"This study assesses the efficacy and safety of olmesartan medoxomil in children ages 1-16 with high blood pressure. After a 5-week blinded treatment period of up to 5 weeks participants can continue to take olmesartan medoxomil (OM) for up to an additional 46 weeks.","primaryOutcome":{"measure":"Least Squares Mean Change From Baseline in Seated Systolic Blood Pressure to the End of Period 2 (3 Weeks)","timeFrame":"Day 0 to 3 weeks","effectByArm":[{"arm":"Cohort A","deltaMin":-0.69,"sd":0.202},{"arm":"Cohort B","deltaMin":-0.85,"sd":0.282},{"arm":"Cohorts A + B","deltaMin":-0.75,"sd":0.165}],"pValues":[{"comp":"OG000","p":"0.0008"},{"comp":"OG000","p":"<0.0001"},{"comp":"OG001","p":"0.0032"},{"comp":"OG001","p":"0.0265"},{"comp":"OG002","p":"<0.0001"},{"comp":"OG002","p":"<0.0001"}]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":65,"countries":["United States","Argentina","Brazil","Chile","Colombia","India","Kenya","Peru","South Africa","Uganda","Zambia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":95},"commonTop":["Headache","Upper respiratory tract infection","Cough","Pyrexia","Nasopharyngitis"]}}